NCT03394937 - Safety of Intranodal ECI-006 in Melanoma Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 27, 2017

Primary Completion Date

December 31, 2020

Study Completion Date

January 29, 2021

Conditions

Melanoma

Interventions

BIOLOGICAL

ECI-006

ECI-006 consists of TriMix and 5 tumor associated antigens mRNA. TriMix is a mixture of mRNAs that encodes potent immune stimulating molecules

Trial Locations (9)

032-004_GZA Sint-Augustinus, Antwerp

032-002_UCL Brussels, Brussels

032-003_AZ Maria Middelares, Ghent

032-001_University Hospital Brussel, Jette

Site 032-007_AZ Sint Maarten, Mechelen

034-001_Hospital Clinic de Barcelona, Barcelona

034-002_MD Anderson Cancer Center, Madrid

034-003_Hospital Universitario Ramon y Cajal, Madrid

034-004_Clinica Universidad de Navarra, Pamplona